If you like healthy food and biotechnology, you’ll love the news. Japan has given the go-ahead to market two CRISPR-edited fishes: a tiger puffer and a red sea bream, both developed by Regional Fish Co. together with Kyoto University and Kindai University.Continue reading
Lulu and Nana are three years old. Amy is the name Nature Biotechnology uses to refer to the third CRISPR baby, born in late spring-early summer 2019. Their health is a closely held secret, that Vivien Marx has investigated for the journal’s December issue. “A full understanding of the health risks faced by the children due to their edited genomes may lie beyond the reach of current technology”, she writes. Despite or maybe because of that, the news feature is well worth reading. Below are a few points:Continue reading
The first Investigational New Drug (IND) application for base-editing technology has been cleared by the Food and Drug Administration. BEAM-101, developed by Beam Therapeutics, is an ex vivo base-editing product candidate, meaning that it uses a modified form of CRISPR capable of making single base changes without double-stranded DNA cleavage.Continue reading
And so it happened. “In a first, surgeons attached a pig kidney to a human, and it worked,” as the New York Times puts it. Data are scarce, however, and all the info we have is from the general media. The kidney came from a GalSafe pig, which is the only one FDA approved so far. But scientists from several companies have already developed pigs much more engineered than that (with three or four porcine genes knocked-out instead of one, and human gene additions). To get an updated picture, we highly recommend this article published in Nature Biotechnology last April.
The list of the latest additions since the beginning of September is impressive. They are called CasMINI (see Molecular Cell), Cas7-11 (see Nature), OMEGAs (see Science), and come respectively from Stanford University (Stanley Qi Lab), MIT (McGovern Institute), and the Broad Institute (Zhang Lab). CasMINI is half the size of Cas9 and could be much easier to deliver. Cas7-11 is the Cas9 of RNA. OMEGAs are a new class of widespread RNA-guided enzymes, thought to be the ancestors of CRISPR.Continue reading
CRISPR-based diagnostic tests for Sars-Cov2 are coming, as you probably know. But what about CRISPR-based antiviral therapy? It would seem a natural outcome for a technology inspired by the way many bacteria fight their viruses. Indeed this kind of research is being pursued in a handful of labs, using a CRISPR enzyme targeting RNA instead of DNA.Continue reading
COVID-19 overshadowed CRISPR’s advancements this year. The July issue of Nature Biotechnology keeps you up with the latest news and trends in genome editing, covering clinical testing, tools, patents, and more.
The idea is bold and seems to have worked fine. By using a DNA cutting enzyme to disrupt the X chromosome, researchers succeeded in distorting the sex ratio of offsprings, eventually leading to the all-male populations collapse. Andrea’s Crisanti and colleagues at the Imperial College London did it to caged Anopheles gambiae mosquitoes in their quest for a genetic strategy to beat malaria. Please see their paper in Nature Biotechnology and the Imperial College press release.Continue reading